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Abstract  
 
When comparing prediction models, it is essential to estimate the magnitude of change 
in performance rather than rely solely on statistical significance. In this paper we 
investigate measures that estimate change in classification performance, assuming two-
group classification based on a single risk threshold. We study the value of a new 
biomarker when added to a baseline risk prediction model. First, simulated data are 
used to investigate the change in sensitivity and specificity (∆Se and ∆Sp). Second, the 
influence of ∆Se and ∆Sp on the Net Reclassification Improvement (NRI; sum of ∆Se and 
∆Sp) and on decision-analytic measures (Net Benefit or Relative Utility) is studied. We 
assume normal distributions for the predictors, and assume correctly specified models 
such that the extended model has a dominating receiver operating characteristic curve 
relative to the baseline model. Remarkably, we observe that even when a strong marker 
is added it is possible that either sensitivity (for thresholds below the event rate) or 
specificity (for thresholds above the event rate) decreases. In these cases decision-
analytic measures provide more modest support for improved classification than NRI, 
even though all measures confirm that adding the marker improved classification 
accuracy. Our results underscore the necessity of reporting ∆Se and ∆Sp separately. 
When a single summary is desired, decision analytic measures allow for a simple 
incorporation of the misclassification costs. 
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INTRODUCTION 
 
The medical literature is abundant with clinical applications of prediction models to 
estimate the risk of having (diagnosis) or developing (prognosis) a targeted condition.1-
12 Such models, if successfully validated, can enhance personalized healthcare by 
supporting individual treatment decisions. With new potentially predictive markers 
becoming rapidly available from genomics, proteomics, imaging, pathology, blood 
analysis, and ultrasonography, substantial effort is put into improving risk prediction. 
This leads to an increasing focus on the evaluation of incremental value of markers 
added to models13,14 and in the comparison of competing prediction models.  
 
When assessing the incremental value of an added marker, recent literature advises only 
one formal test of hypothesis to assess the statistical significance of the marker in a 
multivariable regression model.15-17 After the significance has been established, 
measures quantifying the predictive performance of risk models are important to 
estimate the magnitude of performance improvement. These can be based on the model-
based risks to provide a “global” assessment18, or on risk categories obtained by using 
thresholds to classify patients into two or more groups19,20. Using two groups (low vs. 
high risk) based on a single threshold, the rule might be used to indicate whether or not 
patients should receive treatment. Using two thresholds creates an intermediate risk 
group which may be used to select patients for less invasive treatment or additional 
testing.   
 
The most common “global” measure is the c-statistic, known as the area under the 
receiver operating characteristic (ROC) curve (AUC) for dichotomous outcomes. The 
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AUC difference between models, ∆AUC, has been criticized as being insensitive and hard 
to interpret, motivating novel measures such as Integrated Discrimination Improvement 
and continuous Net Reclassification Improvement.18,21-23 To evaluate improved 
classification, a widely used measure is the Net Reclassification Improvement (NRI).21,24 
NRI is the sum of the net percentage of events reclassified to a higher risk group and the 
net percentage of non-events reclassified to a lower risk group. For classification in two 
groups, NRI equals the sum of the differences in sensitivity and specificity or the 
difference in the Youden index.21  
 
Simultaneously, decision-analytic measures accounting for different misclassification 
costs of events and non-events are gaining attention.25-28 The main measures are the 
increase in Net Benefit (∆NB), increas  in Relative Utility (∆RU), and weighted NRI.22,29,30 
These three measures are transformations of one another and thus always favor the 
same model.31 Similar to the two-group NRI, they can be seen as functions of changes in 
sensitivity and specificity. According to principles of decision analysis, the risk threshold 
used for classification defines the relative misclassification costs32: the odds at threshold 
equal the ratio of the harm of a false positive to the benefit of a true positive. For 
example, a threshold of 20% implies 1:4 odds and thus classifying one true positive is 
worth misclassifying four false positives. This ratio is incorporated into the decision-
analytic measures. On the other hand, the NRI assumes that the cost ratio is a function of 
the event rate and equals the odds of non-events. It is hence theoretically possible that 
the decision-analytic measures do not favor the same model as the NRI.31,33 
 
When one model has a higher sensitivity and specificity than the other, all measures will 
favor this model. However, NRI and decision-analytic measures may differ in their value 
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depending on the adopted risk threshold and the specific changes in sensitivity and 
specificity (∆Se and ∆Sp). When sensitivity is increased but specificity decreased, the 
difference between the two-group NRI and decision-analytic measures may become 
more substantial. Decreasing sensitivity or specificity appears counterintuitive in the 
case of a “useful” marker being added to a baseline model, yet recently such a 
counterintuitive result was reported.34 
 
In this paper we extend these results by investigating ∆Se and ∆Sp under various 
scenarios in which two models are compared, and by studying the differential influence 
of ∆Se and ∆Sp on the NRI and decision-analytic alternatives. We focus on ∆Se and ∆Sp 
as a function of a single risk threshold, and the agreement between the two-group NRI 
and decision-analytic measures. We mainly rely on simulated data involving correctly 
specified models, but illustrate our findings on prediction of coronary heart disease in 
the Framingham data21. 
 
 
METHODS 
 
Simulations 
 
We address three general scenarios: adding a continuous (I) or binary (II) marker to a 
baseline model, and the comparison of a baseline model to a non-nested competing 
model (III). The marker and the set of predictors in a model are each represented by one 
variable. In scenarios I and II we compare a baseline logistic regression model based on 
linear predictor X1 with an extended model where the marker X2 is added. In scenario III 
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we compare two models based on two linear predictors X1 and X2. For scenarios I and III 
we assume X1 and X2 to be normally distributed among events and non-events (with 
standard deviation of 1), and, without loss of generality, set the mean among non-events 
at 0. Given that under normality means and AUCs are mathematically related, the mean 
of X1 and X2 among events is chosen to achieve a specific AUC and ∆AUC.35 Scenario II 
differs from scenario I in that X2 is a binary marker with prevalence among non-events 
and events chosen to achieve a specific ∆AUC. For each scenario, we define a main 
setting as well as a set of variations on that. We assume that the models’ estimated risks 
are well calibrated and that models are correctly specified. This implies that the 
extended or competitor model has a dominant ROC curve relative to the baseline model. 
With calibrated risks we mean that the estimated risks correspond to observed 
proportions: among women with an estimated risk of event of 0.3, 30% are expected to 
have the event. In what follows, the first scenario is described in detail. For the other 
two scenarios, comparable methods are being used which are presented in Web 
Appendix 1. Specific differences are the issues of marker prevalence in scenario II and of 
correlation between models in scenario III. 
 
For the main setting of scenario I, means for X1 and X2 are derived to reflect a baseline 
model with an AUC of 0.7 to which a marker is added that increases AUC by 0.05. The 
correlation between X1 and X2 is set to 0, and the event rate to 10%. The following basic 
variations are considered: (a) the baseline model has a very strong discrimination, i.e. 
AUC = 0.8, while keeping ∆AUC at 0.05; (b) the added marker increases the AUC by 0.01; 
(c) the added marker increases the AUC by 0.1; (d) event rate is 1%; (e) event rate is 
30%; (f) event rate is 70%. Due space constraints we address each variation separately. 
We did address many possible combinations of these variations but did not obtain 
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meaningfully different results. Table 1 provides an overview of the main setting and the 
variations, including AUCs and ∆AUC. 
 
To obtain stable values for model performance on the population level, we simulated a 
dataset containing at least 5 million patients for each setting. We fitted the two models, 
computed classification performance and improvement for thresholds varying from 1% 
to 99% with increments of 1%. Measures for classification improvement included ∆Se 
and ∆Sp, two-group NRI, ∆RU, and ∆NB/event rate. NB corrects the proportion of true 
positives for the proportion of false positives weighted according to the adopted 
misclassification costs, i.e. odds of the risk threshold. NB can be written as follows: 
 
 
#TP #FP*odds(threshold)
NB
N
−
= , (1) 
 
and ∆NB as: 
 
 
TP FP*odds(threshold)
NB
N
∆ − ∆
∆ = , (2) 
 
NB is typically compared to the net benefit of two default strategies: ‘treat all’ (i.e. 
consider everyone high risk) or ‘treat none’ (consider everyone low risk). Finally, RU is 
the proportion of the maximum attainable net benefit that the model captures over the 
best default strategy at the adopted threshold, NBdefault. ∆RU can be written as: 
 
 
NB
RU
event rate NBdefault
∆
∆ =
−
. (3) 
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Note that the best default strategy is ‘treat all’ for thresholds below event rate, and ‘treat 
none’ for thresholds above event rate.  
 
We report ∆RU and ∆NB/event rate because these can be expressed as weighted sums of 
∆Sp and ∆Se and can therefore be compared with NRI as the standard sum of ∆Sp and 
∆Se. ∆NB/event rate is the sum of ∆Se and ‘∆Sp weighted for misclassification costs and 
event rate’ and can thus be seen as an increase in net sensitivity: equivalent to the 
increase in sensitivity at unchanged specificity .31 For thresholds above event rate, ∆RU 
is identical to ∆NB/event rate. Else, ∆RU is the sum of ∆Sp and ‘∆Se weighted for 
misclassification costs and event rate’, thus an increase in net specificity.31 ∆Se is given a 
higher weight than ∆Sp for thresholds below event rate, and lower weight for thresholds 
above event rate. Whether we frame the decision-analytic performance in terms of 
sensitivity or specificity will have an impact on the resulting value. See Web Appendix 2 
for formulas. 
 
Case study: risk prediction for coronary heart disease  
 
A sample of 3264 Framingham Heart Study men and women between 30 and 74 years of 
age without evidence of cardiovascular disease were included in this analysis.  They 
attended their baseline examination between 1987 and 1992 and their risk factors were 
collected. The participants were followed for 10 years for development of coronary 
heart disease (CHD), which included myocardial infarction, angina pectoris, coronary 
insufficiency or CHD death. A Cox model was fitted to obtain the 10-year risk of CHD, 
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using age, sex, diabetes, smoking, and systolic blood pressure as predictors. The 
incremental value of HDL cholesterol is then assessed by adding it to the model21. 
 
 
RESULTS 
 
Added continuous marker (scenario I)  
 
Interplay of changes in sensitivity and specificity. The main setting for the continuous 
maker scenario yielded a completely dominant ROC curve for the extended model 
(Figure 1a). The risk distribution of the extended model had a lower peak and a heavier 
tail showing more cases with increased risks (Figure 1b). However, hardly any risks 
were above 0.5, and hence we used 0.5 as the maximum threshold in the remaining 
graphs. Despite the dominant ROC curve, sensitivity and specificity did not increase at 
every classification threshold (Figures 1c-d). For a subset of thresholds between 0 and 
the event rate, sensitivity decreased when the marker was added. Analogously, 
specificity decreased with thresholds in the middle between event rate and 100%. The 
decrease in performance for events was accompanied by a strong increase in the 
performance for non-events, and vice versa. For thresholds near the event rate, ∆Se and 
∆Sp were both positive. Variations of the main setting, involving changes in the event 
rate or the strength of the baseline model or added marker, yielded analogous results 
that were merely strengthened or weakened depending on the specific variation (Figure 
2).  When varying event rate (Figure 2d-f), we observed similar decreases (up to -2.3%) 
and increases (up to 12%) in sensitivity and specificity. The single difference is that 
results are horizontally shifted to accommodate the different event rates. 
Page 10 of 75
http://mc.manuscriptcentral.com/mdm
Medical Decision Making
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 11 
 
Impact on summary measures. The interplay of ∆Se and ∆Sp created a bimodal 
distribution for the NRI. In all settings the NRI and decision-analytic measures were 
non-negative for all thresholds, and thus acknowledged increased performance when 
adding the new marker despite decreasing ∆Se or ∆Sp for some thresholds.   
 
When ∆Se or ∆Sp was negative, decision-analytic measures gave a numerically more 
modest view of the improved classification. The extent to which the decision-analytic 
measures were more modest depended on whether the improved classification was 
expressed as an increase in net sensitivity or net specificity. If ∆Se was negative, the 
increase was more modest when expressed in terms of net sensitivity. This can be 
explained by the fact that for these thresholds ∆Se was given more relative weight 
compared to ∆Sp. Likewise, if ∆Sp was negative decision-analytic measures were more 
modest when expressed in terms of net specificity. When ∆Se or ∆Sp were both positive, 
the decision-analytic value expressed as the increase in net sensitivity was lower than 
the NRI when the threshold is lower than the event rate but higher for thresholds above 
the event rate. The opposite was true when the decision-analytic measure was 
expressed as the net increase in specificity. By definition, the NRI and the decision-
analytic measures had similar values for thresholds at or near the event rate.  
 
Added binary marker (scenario II) 
 
The main setting now involves a binary marker X2 with a prevalence of 15% in non-
events and 41% in events to achieve a ∆AUC of 0.05. For this setting and its variations, 
the results were very similar to the previous scenario (Web Figures 1-2). We found that 
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∆Se or ∆Sp were often negative despite a dominant ROC curve for the extended model, 
with similar effects of the interplay of ∆Se and ∆Sp on the NRI versus decision-analytic 
measures. Regarding marker prevalence, the lower it is the larger the range of 
thresholds for which sensitivity decreases. With prevalence of 1% in non-events and 
19% in events, sensitivity decreased even for the threshold equal to the event rate. 
 
Comparison of non-nested models (scenario III) 
 
Results for scenario III were entirely comparable to those of the other scenarios (Web 
Figures 3-4).  
 
Case study on CHD risk prediction 
 
The 10-year CHD event rate was 5.6%. Adding HDL cholesterol to the model resulted in 
an adjusted hazard ratio of 0.65 per standard deviation (95% confidence interval: 0.53, 
0.80), suggesting a clear protective association with the risk of CHD. The baseline model 
had an AUC of 0.762, which increased to 0.774 when HDL cholesterol was added (∆AUC 
= 0.012). Classification and difference in classification results for a few possible 
thresholds are consistent with the simulation results although some confidence 
intervals span zero (Table 2). When the common threshold of 20% was used, adding 
HDL increased sensitivity but mildly decreased specificity . The odds of this threshold 
are 1:4, meaning that treating one individual that would develop CHD within 10 years is 
worth the unnecessary treatment of 4 individuals who would not develop CHD. For 
these relative misclassification costs, the improvement in classification performance 
was equivalent to a net increase in sensitivity of 5.3% at unchanged specificity 
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(∆NB/event rate = 0.053). Or, when expressed as the net increase in specificity (Web 
Appendix 2), the improvement was equivalent to an increase in specificity of 1.3% at 
unchanged sensitivity. NRI was positive as well and thus also suggested improved 
classification. 
 
At a threshold of 6%, which has also been advocated, one true positive is worth 16 false 
positives. This threshold was associated with improved sensitivity and mildly improved 
specificity. This was expected since 6% is close to the event rate of 5.6%. At a threshold 
of 4%, for which one true positive is worth 24 false positives, sensitivity worsened 
whereas specificity improved.  
 
 
DISCUSSION 
 
In this paper, we investigated the difference in sensitivity and specificity under various 
scenarios that involve a comparison of predictions models. In addition, we elucidate if 
and how NRI and decision-analytic measures may lead to different conclusions. In 
contrast with intuition, we found that a decrease in sensitivity or specificity often occurs 
at specific thresholds, even when a marker with strong incremental value is added to a 
model or when a competing model has a clearly superior discrimination. At the same 
time the decrease in sensitivity (specificity) will be more than compensated by an 
increase in specificity (sensitivity). This finding was seen for a wide range of settings, 
hence consolidating a similar coincidental finding in a recent study.34 Thus it is 
important to understand that a possible decrease in sensitivity or specificity does not 
necessarily compromise the marker’s incremental value. As a result, it is more 
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informative to report the differences in sensitivity and specificity separately rather than 
their sum in the form of the NRI.36 Although this recommendation was already made in 
the paper that proposed the NRI21, further emphasis is required since many current 
reports focus on the combined NRI rather than its components.  
 
We submit that the robustness of the observed phenomenon was unexpected to us, and 
it appears to have more to do with mathematics than intuition. However, it is logical that 
specificity improves more strongly than sensitivity for low risk thresholds and vice 
versa for high thresholds. The use of a low risk threshold suggests a relative preference 
for true positives over true negatives, and will lead to a relatively high sensitivity for the 
baseline model. This implies that adding a marker leaves more room to improve 
specificity than sensitivity. The phenomenon of decreasing sensitivity or specificity 
becomes less apparent when the discrimination performance of the baseline model is 
better but also when the discrimination performance of the added marker or competitor 
model is better (panels A and C in Figure 1 and Web Figures 2 and 4): eventually, higher 
discrimination will by definition lead to perfect sensitivity and specificity. 
 
At the population level, the NRI and decision-analytic alternatives are likely to be 
different in magnitude mainly when ∆Se and ∆Sp are different in sign, which usually 
happens when the threshold is in the middle between event rate and either 0 or 1. If a 
single summary measure is desired in the two-group setting, we recommend presenting 
such measures alongside differences in sensitivity and specificity, given that decision-
analytic measures allow explicit incorporation of the misclassification costs. These 
performance measures are essential to estimate the magnitude of change in 
classification performance, whereas formal hypothesis testing of the incremental value 
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of an added marker should focus on the marker’s coefficient in a multivariable 
regression model.15-17 
 
The decision-analytic measures can be framed as a difference in net sensitivity or as a 
difference in net specificity31, and we believe that it is useful to express these measures 
from both viewpoints. In this work we used NB/event rate rather than NB itself in order 
to better compare it with NRI and RU. While NB/event rate can be seen as a net 
sensitivity, NB expresses the result on an absolute scale as the net proportion of true 
positives. The absolute expression can be seen as clinically more relevant as it is not 
conditional on the event rate but rather expresses the result at the level of the patients 
themselves. Even then, NB can be reworked to give the net proportion of true negatives. 
On the contrary, RU calculations depend on whether the threshold is below or above the 
event rate. In the former case the default strategy is ‘treat all’ and RU is expressed in the 
form of a net specificity, in the latter case it is the other way around. This makes sense, 
because ‘treat all’ has 100% sensitivity and 0% specificity such that comparing a model 
with this default strategy is logically done on the specificity scale. 
 
We acknowledge that performing simulation studies under the assumption of normality 
of predictors and based on one specific model type (logistic regression) may not always 
generalize to situations where this assumption is violated. We do believe, however, that 
our results are generalizable to many settings. First, the assumption of normality for a 
model and for a single added continuous marker is reasonable. Linear predictors for 
prediction models quite often approach a normal distribution for events and non-events. 
Also, non-normally distributed markers can very often be made normally distributed 
through a simple transformation. Note that the assumption of normality has frequently 
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being used in similar work.15,18,37 Second, one of the addressed scenarios involved the 
addition of a binary marker to a prediction model. Results for this scenario were similar 
to those for other scenarios. Third, under normality with equal standard deviations 
among events and non-events and with equal correlation between baseline model and 
marker for events and non-events, the logistic regression is the correct mathematical 
formulation of the link between predictors and outcome.37 Fourth, we performed a set of 
simulations under different conditions (1 - added marker is lognormally distributed 
among events and non-events; 2 - baseline model consists of four binary markers and 
added marker is binary as well) and using different model types (probit regression, 
Poisson regression, and support vector machines), and obtained similar results (Web 
Appendix 3).  
 
A drawback of this work is that we focused on correctly specified models. 
Misspecification can refer to lack of calibrated risks, inappropriate modeling of 
predictors with strongly nonlinear effects, or omission of an important interaction effect. 
Full investigation of misspecification is a subject on its own that would dilute the main 
message of the current work. We did, however, carry out simulations under a limited set 
of misspecification settings. More specifically we investigated situations where the 
model with an added continuous marker overfits risks, misses a quadratic effect of the 
marker, or missed an interaction between the marker and information in the baseline 
model  (Web Figure 5). These settings generally showed a similar pattern for ∆Se and 
∆Sp, with one of them becoming negative for some risk thresholds. ∆NB was always 
lower under misspecification compared to correct specification, with even negative 
values observed for some risk thresholds in all three settings. NRI was higher when the 
model with the added marker overfitted the risk as compared to a well calibrated model, 
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especially as the risk threshold moved away from event rate. This undesirable result is 
in line with previous reports.38 
 
This work focused on results on the population level by considering an enormous 
sample size, and suggested that NRI and decision-analytic measures are consistent in 
sign for correctly specified models. These results give a reference of what may be 
obtained in studies on the incremental value of novel markers or on the performance of 
non-nested models. For finite sample sizes (e.g. the presented case study), however, 
results can be uncertain and inconsistency in sign may nevertheless occur. 31,33 To 
demonstrate this we simulated 1000 datasets containing 1000 patients for the main 
setting of scenario 1, and computed how often the NRI and decision-analytic measures 
were inconsistent in sign (Figure 3). The proportion of inconsistencies was near 0 when 
the threshold equaled the true event rate, although due to sampling variability of the 
event rate the proportion was not exactly 0. When the threshold was further from the 
true event rate, the proportion increased. When the threshold approaches 0 or 1, all 
measures of improved classification approach 0 by definition and hence the proportion 
of inconsistencies does too.  
 
Often, more than two thresholds are defined to delineate three or more risk groups to 
allow several options for managing patients.24 Evaluation of improved classification is 
more complex in such cases and, although possible, the extensions of decision-analytic 
measures to these situations are not straightforward. As a result, the applicability of 
decision-analytic measures in addition to the NRI components, ∆Se and ∆Sp, is clear in 
the two-group setting, but it needs further investigation in the multiple-group setting. 
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CONCLUSION 
 
When comparing prediction models, it is essential to estimate the magnitude of change 
in performance rather than rely on statistical significance. In contrast with what could 
be expected intuitively, sensitivity or specificity may decrease even when the ROC curve 
of one model uniformly dominates the ROC curve of the other model. The NRI and 
decision-analytic measures will agree in sign in reasonable scenarios. But the latter 
measures will generally give a numerically more modest impression of the improved 
classification performance of the added marker or competing model. When estimating 
the difference in the two-group classification performance of two risk models, we 
recommend reporting the differences in sensitivity and specificity separately. When a 
combined measure is desired, decision-analytic measures such as NB and RU have the 
advantage of explicit incorporation of costs. 
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Table 1. Settings for Assessing the Added Value of a Continuous Marker.  
 
Event rate Mean of X1  Mean of X2 
AUC  
Baseline model 
AUC  
Extended model 
∆AUC 
Main setting     
10% 0.742 0.6 0.70 0.75 0.05 
Variations     
Stronger baseline model   
10% 1.19 0.86 0.80 0.85 0.05 
Weaker or stronger added marker   
10% 0.742 0.25 0.70 0.71 0.01 
10% 0.742 0.931 0.70 0.80 0.1 
Higher or lower event rate   
1% 0.742 0.6 0.70 0.75 0.05 
30% 0.742 0.6 0.70 0.75 0.05 
70% 0.742 0.6 0.70 0.75 0.05 
AUC, area under the receiver operating characteristic curve; ∆AUC, 
difference in area under the receiver operating characteristic curve 
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Table 2. Added Value of HDL Cholesterol in the Prediction of Coronary Heart Disease. 
 
 Risk threshold 
 4% 6% 20% 
Baseline model    
   Sensitivity 87% 70% 13% 
   Specificity 51% 68% 97% 
Classification improvement when adding HDL (95% CI)  
   ∆Sens -2.7 (-6.3; 0.6) 6.0 (1.2; 11.1) 6.0 (2.3; 10.9) 
   ∆Spec 2.1 (1.0; 3.3) 0.2 (-0.9; 1.4) -0.2 (-0.7; 0.3) 
   NRI -0.006 (-0.045; 0.030) 0.062 (0.013; 0.113) 0.058 (0.020; 0.108) 
   ∆RU -0.018 (-0.071; 0.032) 0.063 (0.013; 0.113) 0.053 (0.008; 0.106) 
   ∆NB/event rate -0.012 (-0.050; 0.023) 0.063 (0.013; 0.113) 0.053 (0.008; 0.106) 
CI, confidence interval; Sens, difference in sensitivity; Sens, difference in specificity; 
NRI, net reclassification improvement; NB, difference in net benefit; RU, difference in 
relative utility.  
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Figure Legends 
 
Figure 1. Adding a continuous marker to a baseline prediction model: ROC curves (A), 
risk distributions (B), sensitivity and specificity by risk threshold (C), measures to assess 
improvement in classification (D). The event rate is 10%, the AUC of the baseline model 
is 0.70 and of the model with the marker is 0.75. 
 
Figure 2. Adding a continuous marker to a baseline prediction model: assessment of 
improved classification for variations of the main setting. (A) baseline model has strong 
discrimination, (B) added marker increases AUC by 0.01, (C) added marker increases 
AUC by 0.1, (D) event rate 1%, (E) event rate 30% (F) event rate 70%. 
 
Figure 3. Adding a continuous marker to a baseline prediction model: finite sample 
results showing the proportion of 1000 bootstrap samples where NRI and ∆NB differed 
in sign as a function of risk threshold. 
 
Web Figure 1. Adding a binary marker to a baseline prediction model: ROC curves (A), 
risk distributions (B), sensitivity and specificity by risk threshlod (C), measures to assess 
improvement in classification (D). The event rate is 10%, the AUC of the baseline model 
is 0.70 and of the model with the marker is 0.75 (marker prevalence is 15% among non-
events and 41% among events). 
 
Web Figure 2. Adding a binary marker to a baseline prediction model: assessment of 
improved classification for variations of the main setting. (A) baseline model has strong 
discrimination, (B) added marker increases AUC by 0.01, (C) added marker increases 
AUC by 0.1, (D) event rate 1%, (E) event rate 30%, (F) event rate 70%, (G) prevalence of 
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binary marker is 50% for non-events while maintaining ∆AUC of 0.5, (H) prevalence of 
binary marker is 1% for non-events while maintaining ∆AUC of 0.5. 
 
Web Figure 3. Comparing two non-nested models: ROC curves (A), risk distributions (B), 
sensitivity and specificity by risk threshold (C), measures to assess improvement in 
classification (D). The event rate is 10%, the AUC of the baseline model is 0.70 and of the 
competitor model is 0.75, and the correlation between the linear predictors of the two 
models is 0.5. 
 
Web Figure 4.  Comparing two competing models: assessment of improved classification 
for variations of the main setting. (A) baseline model has strong discrimination, (B) ∆AUC 
is 0.01, (C) ∆AUC is 0.1, (D) event rate 1%, (E) event rate 30% (F) event rate 70%, (G) 
competing models are strongly correlated (correlation 0.75). 
 
Web Figure 5. Adding a continuous marker to a baseline prediction model when the 
model with marker is misspecified: assessment of improved classification. (A) Extended 
model is overfit, (B) Missed interaction effect between marker and baseline model as well 
as missed quadratic effects for marker and baseline model (effects introduced by 
assuming correlation of marker with baseline model in events), (C) Missed quadratic 
effect of marker (effect introduced by increasing SD of added marker for non-events to 2). 
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Web Figure 1.  
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Web Figure 2.  
 
 A (stronger baseline model) B (weaker added marker) 
 
  
 
 
 C (stronger added marker) D (event rate 1%) 
 
 
  
 
 E (event rate 30%) F (event rate 70%) 
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G (higher prevalence of marker) H (lower prevalence of marker) 
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Web Figure 3.  
 
 A B 
 
 
 
 
 
 
  C D 
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Web Figure 4.  
 
  A (stronger baseline model) B (weaker competitor model) 
 
 
 
 
 C (stronger competitor model) D (event rate 1%) 
 
  
  
 
 E (event rate 30%) F (event rate 70%) 
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(G) higher correlation between competing models 
 
  
 
 
 
Page 37 of 75
http://mc.manuscriptcentral.com/mdm
Medical Decision Making
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 1 
Web Figure 5.  
 
A (model with marker is overfit) 
 
 
 
 
B (missed quadratic effect of marker) 
 
 
 
 
C (missed interaction between model and marker) 
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Web Appendix 1: Settings for scenarios II (adding a binary marker to a prediction 
model) and III (comparing non-nested prediction models) 
 
Adding a binary marker – The main difference here is that X2 is now binary. This is 
obtained by dichotomizing a normally distributed variable. The AUCs of the baseline and 
extended models is set to the same values as in the main setting of scenario I. In the 
main setting the prevalence of the binary marker among non-events is set at 15%, 
whereas the prevalence among events is 41% to obtain the desired ∆AUC of 0.05. Again, 
X1 and X2 are uncorrelated and event rate is 10%. Variations considered are (Table A1): 
(a) the baseline model has an AUC of 0.8 while keeping ∆AUC at 0.05; (b) the added 
marker has a weak incremental value: prevalence among events 25% and ∆AUC is 0.01; 
(c) the added marker has a strong incremental value: prevalence among events 56% and 
∆AUC is 0.1; (d) event rate is 1%; (e) event rate is 30%; (f) event rate is 70%; (g) marker 
prevalence among non-events is 50%, such that prevalence among events is 78% to 
retain the original ∆AUC of 0.05; (h) marker prevalence among non-events is 1% and 
among events is 19% to retain the original ∆AUC. 
 
Comparison of non-nested models – In this situation X1 and X2 represent predictors from 
two competing and non-nested models. In the main setting, the competitor model based 
on X2 has an AUC that is 0.05 higher than the AUC of the baseline model based on X1 
which is set at 0.7. As it is reasonable to assume that good competing models are 
correlated, we set the correlation between X1 and X2 to 0.5 among non-events as well as 
among events. The following variations are considered (Table A2): (a) the baseline 
model has an AUC of 0.8 while keeping ∆AUC at 0.05; (b) the competitor model has a 
small AUC advantage of 0.01; (c) the competitor model has a large AUC advantage of 0.1; 
(d) event rate is 1%; (e) event rate is 30%; (f) event rate is 70%; (g) correlation between 
X1 and X2 is 0.75. 
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Table A1. Settings for Assessing the Incremental Value of a Binary Marker 
 
Event rate Mean of X1  
Prevalence of 
marker among  
non-events and 
events 
AUC 
Baseline 
model 
AUC 
Extended 
model 
∆AUC 
Main setting 
10% 0.742 15% and 41% 0.7 0.75 0.05 
Variations 
Stronger baseline model    
10% 1.19 15% and 53% 0.8 0.85 0.05 
Weaker or stronger added marker    
10% 0.742 15% and 25% 0.7 0.71 0.01 
10% 0.742 15% and 56% 0.7 0. 8 0.1 
Higher or lower event rate    
1% 0.742 15% and 41% 0.7 0.75 0.05 
30% 0.742 15% and 41% 0.7 0.75 0.05 
60% 0.742 15% and 41% 0.7 0.75 0.05 
Higher or lower prevalence of marker   
10% 0.742 50% and 78% 0.7 0.75 0.05 
10% 0.742 1% and 19% 0.7 0.75 0.05 
AUC, area under the receiver operating characteristic curve; ∆AUC, 
difference in area under the receiver operating characteristic curve 
 
 
Table A2.  Settings for the Comparison of Non-nested Models 
 
Event rate Mean of X1  Mean of X2 
Correlation 
X1-X2 
AUC 
Baseline 
model 
AUC 
Competitor 
model 
∆AUC 
Main setting      
10% 0.742 0.954 0.5 0.7 0.75 0.05 
Variations      
Stronger baseline model    
10% 1.19 1.466 0.5 0.8 0.85 0.05 
Weaker or stronger competitor model    
10% 0.742 0.783 0.5 0.7 0.71 0.01 
10% 0.742 1.19 0.5 0.7 0.71 0.1 
Higher or lower event rate    
1% 0.742 0.954 0.5 0.7 0.75 0.05 
30% 0.742 0.954 0.5 0.7 0.75 0.05 
70% 0.742 0.954 0.5 0.7 0.75 0.05 
Higher correlation between models    
10% 0.742 0.954 0.75 0.7 0.75 0.05 
AUC, area under the receiver operating characteristic curve; ∆AUC, difference 
in area under the receiver operating characteristic curve 
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Web Appendix 2: Formulas for NRI, ∆NB/event rate, and ∆RU 
 
The NRI, ∆NB/event rate and ∆RU can be written as a function of ∆Se and ∆Sp [31]. If we 
denote the threshold by T and the event rate by ER, the formulas are as follows: 
 
( )
( )
( )( )
( )
( )
( )
( )
( )
( )
NRI Se Sp,
NB Se Sp,
NB
Se Sp,
1
Se Sp, if 
RU .
Se Sp,if 
odds T
ER
odds ER
odds ER
odds T ER odds T
odds ER
T ER
odds T
odds T
T ER
odds ER
= ∆ + ∆
∆ = ∆ + ∆
∆
= ∆ + ∆
−

∆ + ∆ <

∆ = 
∆ + ∆ ≥

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Web Appendix 3: beyond normality and the logistic regression model 
 
In this appendix we extend the simulations to other algorithms than logistic regression,  
more specifically probit regression, Poisson regression, and support vector machines 
(SVM). In addition we investigate whether the results generalize to (1) a situation where 
the added marker is lognormal among events and non-events and (2) a situation, 
potentially less realistic, where the baseline model contains multiple binary markers 
and the added marker is binary as well. T An overview of the eleven settings addressed 
in this Appendix is provided in Table A3. We used simulated data of sample size 500,000, 
except for the SVM analyses where computational issues made us choose a sample size 
of 5,000. The results for the ‘normal+normal’ situation are shown in Figure A1, for the 
‘normal+lognormal’ situation in Figure A2, and for the ‘binary+binary’ situation in 
Figure A3. These figures show that the main findings generalize to other prediction 
algorithms and to situations where the baseline and/or added markers are non-normal.
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Table A3. Settings for Assessing the Incremental Value of a Binary Marker 
 
Baseline 
(AUC) 
Added marker 
(AUC) 
Sample 
size 
Event 
rate 
Algorithm 
Normal Normal 500,000 0.1 Logistic regression 
(0.70) (0.75) 500,000 0.1 Probit regression 
  500,000 0.1 Poisson regression1 
  5,000 0.1 Support Vector Machine2 
Normal Lognormal 500,000 0.1 Logistic regression 
(0.70) (0.80) 500,000 0.1 Probit regression 
  500,000 0.1 Poisson regression1 
  5,000 0.1 Support Vector Machine2 
4 binary variables3 Binary3 500,000 0.1 Logistic regression 
(0.63) (0.70) 500,000 0.1 Probit regression 
  500,000 0.1 Poisson regression1 
Note: in each setting, the variables are uncorrelated. 
1 Following Zou [39]. 
2 More specifically, a Bayesian least squares support vector machine with a linear kernel was used 
[40-42]. This analysis was done in Matlab version R2007a (www.mathworks.com) using the 
LSSVMlab toolbox. 
3 The four binary markers in the baseline model each have a prevalence of 15% among non-events 
and 25% among events. The added binary marker has a prevalence of 15% among non-events and 
41% among events. 
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Figure A1. Assessment of improved classification in the ‘normal+normal’ setting. Using 
(A) logistic regression, (B) probit regression, (C) Poisson regression, or (D) support 
vector machines. 
 
 A (logit) B (probit) 
 
 
 
 
 
 C (Poisson) D (SVM) 
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Figure A2. Assessment of improved classification in the ‘normal+lognormal’ setting. Using 
(A) logistic regression, (B) probit regression, (C) Poisson regression, or (D) support 
vector machines. 
 
 A (logit) B (probit) 
 
 
 
 
 
 C (Poisson) D (SVM) 
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Figure A3. Assessment of improved classification in the ‘binary+binary’ setting. Using (A) 
logistic regression, (B) probit regression, or (C) Poisson regression. 
 
 A (logit) B (probit) 
 
 
 
 
 
 C (Poisson)  
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